艾迪药业(688488.SH)：上半年净利润919.1万元 同比扭亏为盈

Core Insights - The company reported a total operating revenue of 362.48 million yuan for the first half of the year [1] - Sales revenue from HIV innovative drugs reached 129.38 million yuan, marking a year-on-year growth of 58.49% [1] - The company achieved a net profit attributable to shareholders of 9.19 million yuan, reversing from a loss in the same period last year [1]